A drug approval, an outbreak, a trial result, a coverage decision. Each entry reads one story for patients, clinicians, payers and the companies involved, grades the evidence behind the headline, and keeps a study's finding apart from a press release's claim. Never care guidance.
Drugs and devices · public health · trials and evidence · hospitals, insurers and policy
Pennsylvania's decision to withdraw expanded disease-surveillance rulemaking amid its worst measles outbreak in over three decades leaves state health officials without tools they sought just as the outbreak accounts for nearly a quarter of all U.S. cases.
Read the research →The DRC's Ebola outbreak has become a Bundibugyo-strain epidemic without a purpose-built vaccine, with a roughly 48% case fatality ratio and active spread into North Kivu and two new border-adjacent health zones that raise regional containment risk.
Read the research →Onswik gives Lilly a second weekly-insulin option competing directly with Novo Nordisk's six-months-earlier Awiqli on convenience and price rather than superior glycemic control, since both hit only noninferiority endpoints against daily basal insulin.
Read the research →Every entry here was one headline, run the day it broke. Paste yours and get the same read: who it affects, what is established, what to watch.